(Q37812058)

23 August 2017

title

Therapeutic trials in nonalcoholic steatohepatitis: insulin sensitizers and related methodological issues (English)

1 reference

23 August 2017

0 references

1 reference

Vlad Ratziu

1

1 reference

23 August 2017

Stephen Caldwell

series ordinal

2

1 reference

23 August 2017

Brent A Neuschwander-Tetri

series ordinal

3

1 reference

23 August 2017

language of work or name

English

0 references

publication date

1 December 2010

1 reference

23 August 2017

1 reference

23 August 2017

volume

52

1 reference

23 August 2017

issue

6

1 reference

23 August 2017

page(s)

2206-2215

1 reference

Role of AMP-activated protein kinase in mechanism of metformin action

23 August 2017

cites work

1 reference

Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial

21 January 2018

1 reference

A position statement on NAFLD/NASH based on the EASL 2009 special conference

21 January 2018

1 reference

7 January 2021

Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis

1 reference

7 January 2021

Acute antihyperglycemic mechanisms of metformin in NIDDM. Evidence for suppression of lipid oxidation and hepatic glucose production

1 reference

7 January 2021

Metformin reverses fatty liver disease in obese, leptin-deficient mice

1 reference

7 January 2021

Metformin in non-alcoholic steatohepatitis.

1 reference

7 January 2021

A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease

1 reference

7 January 2021

Metformin in the treatment of patients with non-alcoholic steatohepatitis

1 reference

7 January 2021

Clinical trial: insulin-sensitizing agents may reduce consequences of insulin resistance in individuals with non-alcoholic steatohepatitis

1 reference

7 January 2021

Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial

1 reference

7 January 2021

Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis.

1 reference

7 January 2021

Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes

1 reference

7 January 2021

The nuclear receptor PPARgamma - bigger than fat

1 reference

7 January 2021

The effect of thiazolidinediones on adiponectin serum level: a meta-analysis

1 reference

7 January 2021

Inverse association between liver fat content and hepatic glucose uptake in patients with type 2 diabetes mellitus

1 reference

7 January 2021

Effects of pioglitazone on lipid and lipoprotein metabolism

1 reference

7 January 2021

Thiazolidinediones: metabolic actions in vitro

1 reference

7 January 2021

Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial

1 reference

7 January 2021

A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis

1 reference

7 January 2021

A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis

1 reference

7 January 2021

Influence of local reference populations on upper limits of normal for serum alanine aminotransferase levels

1 reference

7 January 2021

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis

1 reference

7 January 2021

Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis

1 reference

7 January 2021

Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-γ ligand rosiglitazone

1 reference

7 January 2021

Sampling Variability of Liver Biopsy in Nonalcoholic Fatty Liver Disease

1 reference

7 January 2021

A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis

1 reference

7 January 2021

The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis

1 reference

7 January 2021

Changes in serum adipokine levels during pioglitazone treatment for nonalcoholic steatohepatitis: relationship to histological improvement

1 reference

7 January 2021

Thiazolidinediones for the treatment in NASH: sustained benefit after drug discontinuation?

1 reference

7 January 2021

Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes

1 reference

7 January 2021

Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis.

1 reference

7 January 2021

Triglyceride accumulation protects against fatty acid-induced lipotoxicity

1 reference

7 January 2021

Values and limitations of serum aminotransferases in clinical trials of nonalcoholic steatohepatitis

1 reference

7 January 2021

Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: The central role of nontriglyceride fatty acid metabolites

1 reference

7 January 2021

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

1 reference

7 January 2021

Cardiovascular safety of rosiglitazone

1 reference

7 January 2021

Data and safety monitoring of rosiglitazone trials

1 reference

7 January 2021

Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis

1 reference

7 January 2021

The rosiglitazone story--lessons from an FDA Advisory Committee meeting

1 reference

7 January 2021

Risk of acute myocardial infarction in patients treated with thiazolidinediones or other antidiabetic medications

1 reference

7 January 2021

Relationship between thiazolidinedione use and cardiovascular outcomes and all-cause mortality among patients with diabetes: a time-updated propensity analysis

1 reference

7 January 2021

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

1 reference

7 January 2021

Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials

1 reference

7 January 2021

Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial

1 reference

7 January 2021

Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis

1 reference

7 January 2021

Thiazolidinedione use and bone loss in older diabetic adults

1 reference

7 January 2021

Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes

1 reference

7 January 2021

Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients

1 reference

7 January 2021

Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors.

1 reference

7 January 2021

The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population

1 reference

7 January 2021

Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease

1 reference

7 January 2021

A novel diagnostic biomarker panel for obesity-related nonalcoholic steatohepatitis (NASH).

1 reference

7 January 2021

Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study

1 reference

7 January 2021

Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease

1 reference

7 January 2021

Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers

1 reference

7 January 2021

Prevalence of and risk factors for hepatic steatosis in Northern Italy

1 reference

7 January 2021

A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis

1 reference

7 January 2021

Identifiers

DOI

10.1002/HEP.24042

1 reference

23 August 2017

1 reference